Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Binding of prostate-specific membrane antigen to dendritic cells: a critical step in vaccine preparation.

Cytotherapy - 1 Jan 2009

Garetto Stefano, Sizzano Federico, Brusa Davide, Tizzani Alessandro, Malavasi Fabio, Matera Lina

Abstract excerpt

BACKGROUND AIMS: Dendritic cell (DC)-based vaccines hold promise as a safe therapy for prostate cancer (PCa), and prostate-specific membrane antigen (PSMA) fulfils the requirements for a tumor-associated antigen (TAA) to be clinically effective. We evaluated the actual binding of selected HLA-A2-...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Cancer Vaccines
Share to Cell Differentiation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dendritic Cells

Share to Fluorescence Resonance Energy Transfer

Share to HLA-A2 Antigen

Share to Peptides

Share to Prostate-Specific Antigen

Source

Identifiers

PMID: 19929472
DOI: 10.3109/14653240903164971

Genes

CCR7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19929472-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Binding of prostate-specific membrane antigen to dendritic cells: a critical step in vaccine preparation.PMID 19929472Read ↗

Impaired monocyte-derived dendritic cell phenotype in prostate cancer patients: A phenotypic comparison with healthy donors.Semantic proximity Read ↗

Identification of MHC class II-restricted T-cell epitopes in prostate-specific membrane antigen.Semantic proximity Read ↗

Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles.Semantic proximity Read ↗

An HLA-A3-binding prostate acid phosphatase-derived peptide can induce CTLs restricted to HLA-A2 and -A24 alleles.Semantic proximity Read ↗

PSMA-Specific Car-Engineered T Cells for Prostate Cancer: CD28 outperforms combined CD28-41BB “Super- stimulation”Semantic proximity Read ↗

Case Report: Targeting of individual somatic tumor mutations by multipeptide vaccination tailored for HLA class I and II presentation induces strong CD4 and CD8 T-cell responses in a patient with metastatic castration sensitive prostate cancer.Semantic proximity Read ↗

Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics.Semantic proximity Read ↗

Dendritic cell vaccines in melanoma: from promise to proof?Semantic proximity Read ↗

Prostate-related antigen-derived new peptides having the capacity of inducing prostate cancer-reactive CTLs in HLA-A2+ prostate cancer patients.Semantic proximity Read ↗

A preliminary study on the activation and antigen presentation of hepatitis B virus core protein virus-like particle-pulsed bone marrow-derived dendritic cells.Semantic proximity Read ↗

Lentivirus-induced ‘Smart’ dendritic cells: Pharmacodynamics and GMP-compliant production for immunotherapy against TRP2-positive melanomaSemantic proximity Read ↗

Direct activation of human dendritic cells by particle-bound but not soluble MHC class II ligand.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.